World Health Organization Raises Warning Over Severe Shortage of Weight-Loss Medications
Less than 10% of patients that would benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it publishes its initial advice on the drugs.
With more than one billion individuals worldwide now living with obesity, it is advocating for more widespread and fairer access to these injectable treatments.
According to projections, over two billion could be living with obesity by 2030 unless action is taken.
"The latest guidance affirms that obesity is a long-term condition that can be addressed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant barriers to universal availability to the jabs that can help people shift considerable weight, explains the organization.
Weight-Loss Drug Scarcity
Even in the current best projected case, the supply of GLP-1 therapies would only suffice for about 100 million people – under 10% of the global need, according to the WHO.
The guideline calls on nations and manufacturers to widen access, via measures including patent sharing.
Exclusive production rights on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
How Obesity Drugs Operate
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and increase satiety so people eat less.
Patients commonly see weight reduction after several weeks of starting on the regular doses.
Research points to patients may see weight return within a year of discontinuing the treatment, as their typical food cravings return.
To be carrying excess weight elevates your likelihood for developing health problems, such as type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight affects individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the health agency.
